Drug Development's Preclinical Bottleneck
This article was originally published in Start Up
Executive Summary
Thanks to genomics, combinatorial chemistry, and high-throughput screening, pharmaceutical companies have more drug leads than ever. But which are the drugs? Start-up firms with faster, smarter approaches to preclinical testing may help sort out the answers. Information technology will play a key role in lead optimization as new firms with simulation software are helping drug developers plot development strategies earlier than ever.
You may also be interested in...
Critical Partners on FDA's Critical Path
The new C-Path Institute in Tucson, Arizona sits at the heart of FDA's intentions to moderize the drug development process. It has three foundling partners: the Institute (which came out of the existing CERT at the University of Arizona), FDA and SRI. These are the key people in the partnership.
A Critical Test for FDA's Critical Path Initiative
FDA wants to reverse the deline in NDA approvals; the agency may have a key ally at a new center in Arizona.
The People Business: The Renaissance of Population Genetics
New technologies enable the rapid processing of genetic information, but since gene data isn't associated with specific diseases and diseased tissues, in and of itself it isn't clinically useful. A new breed of start-ups aims to provide both the phenotypic and genotypic sides of the equation by creating databases of patients and patient samples. Still unclear is how much drug firms will pay for disease-associated gene data; genetics firms are taking various approaches to monetizing their databases, from focusing initially on high-value diagnostics to creating true target-discovery businesses, to selling their data along with associated software and services. There are also ethical issues to hammer out. The new companies must take care to protect patients' rights. They must consider the need for explicit consent to use the information collected from patients, especially when they are participating in research whose purpose is as yet undefined.